Trinity Biotech Plc Stock Performance

TRIB Stock  USD 0.91  0.12  15.19%   
Trinity Biotech has a performance score of 1 on a scale of 0 to 100. The entity has a beta of 0.37, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Trinity Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Trinity Biotech is expected to be smaller as well. Trinity Biotech plc right now has a risk of 8.13%. Please validate Trinity Biotech sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to decide if Trinity Biotech will be following its existing price patterns.

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Trinity Biotech plc are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating forward indicators, Trinity Biotech may actually be approaching a critical reversion point that can send shares even higher in February 2026. ...more
Last Split Factor
1:5
Dividend Date
2015-07-01
Ex Dividend Date
2015-06-05
Last Split Date
2024-02-23
1
USWNTs Emma Hayes weighs in on Trinity Rodmans future, NWSL salary cap
11/19/2025
2
Icon Advisers Inc. Co. Reduces Holdings in Trinity Industries, Inc. TRN
12/01/2025
3
Spirit cautiously optimistic about Trinity Rodman negotiations and working with NWSL
12/10/2025
4
Trinity Biotech Stock Jumps 60 percent After Major Breakthrough
12/23/2025
5
What Caused Multi Ways Holdings To Soar Nearly 49 percent In After-Hours Trading
12/24/2025
6
Callous day care owner allegedly killed infant by bashing his head into floor during diaper change
12/31/2025
7
Trinity Industries, Inc. Completes Railcar Partnership Restructuring Raises EPS Guidance
01/06/2026
8
The best film TV to watch in 2026
01/07/2026
9
USWNT January roster Three thoughts as Trinity Rodman returns in 2026
01/08/2026
10
Trinity Industries Is Up 5.1 percent After Raising 2025 EPS Guidance To 3.053.20 - Whats Changed
01/12/2026
11
Unpacking Q3 Earnings Trinity In The Context Of Other Heavy Transportation Equipment Stocks
01/16/2026
12
Starlight Investments clbre lachvement de Trinity Heights, la nouvelle tour rsidentielle de 60 tages de Manchester.
01/20/2026
13
Trinity Rodman becomes highest-paid womens soccer player in the world with Washington Spirit deal
01/23/2026
Begin Period Cash Flow3.7 M
Total Cashflows From Investing Activities-23 M

Trinity Biotech Relative Risk vs. Return Landscape

If you would invest  102.00  in Trinity Biotech plc on October 27, 2025 and sell it today you would lose (11.00) from holding Trinity Biotech plc or give up 10.78% of portfolio value over 90 days. Trinity Biotech plc is currently generating 0.1122% in daily expected returns and assumes 8.1301% risk (volatility on return distribution) over the 90 days horizon. In different words, 73% of stocks are less volatile than Trinity, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Trinity Biotech is expected to generate 11.1 times more return on investment than the market. However, the company is 11.1 times more volatile than its market benchmark. It trades about 0.01 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

Trinity Biotech Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Trinity Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Trinity Biotech plc, and traders can use it to determine the average amount a Trinity Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average Trinity Biotech is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Trinity Biotech by adding it to a well-diversified portfolio.

Trinity Biotech Fundamentals Growth

Trinity Stock prices reflect investors' perceptions of the future prospects and financial health of Trinity Biotech, and Trinity Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Trinity Stock performance.

About Trinity Biotech Performance

By analyzing Trinity Biotech's fundamental ratios, stakeholders can gain valuable insights into Trinity Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Trinity Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Trinity Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 158.66  163.83 
Return On Tangible Assets(0.70)(0.67)
Return On Capital Employed(0.27)(0.25)
Return On Assets(0.28)(0.26)
Return On Equity 0.81  0.85 

Things to note about Trinity Biotech plc performance evaluation

Checking the ongoing alerts about Trinity Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Trinity Biotech plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Trinity Biotech plc had very high historical volatility over the last 90 days
Trinity Biotech plc has some characteristics of a very speculative penny stock
Trinity Biotech plc has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 61.55 M. Net Loss for the year was (31.79 M) with profit before overhead, payroll, taxes, and interest of 21.44 M.
Trinity Biotech plc currently holds about 10.01 M in cash with (4.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41.
Trinity Biotech plc has a poor financial position based on the latest SEC disclosures
Roughly 66.0% of the company shares are owned by institutional investors
Latest headline from thelincolnianonline.com: Cingulate Inc. Receives Average Rating of Moderate Buy from Brokerages
Evaluating Trinity Biotech's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Trinity Biotech's stock performance include:
  • Analyzing Trinity Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Trinity Biotech's stock is overvalued or undervalued compared to its peers.
  • Examining Trinity Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Trinity Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Trinity Biotech's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Trinity Biotech's stock. These opinions can provide insight into Trinity Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Trinity Biotech's stock performance is not an exact science, and many factors can impact Trinity Biotech's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Trinity Stock analysis

When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Commodity Directory
Find actively traded commodities issued by global exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation